个人中心 - 老虎社区

林欣霓

IP属地：未知

帖子 · 44帖子 · 44
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 林欣霓林欣霓
  ·2021-11-11
  Wood saids The next big 'Aha moment' for the market is when we see some success on [Tesla's] full self-driving autonomous front[微笑]
  非常抱歉，此主贴已删除
  960 1
  2
  分享
  举报
- 林欣霓林欣霓
  ·2021-11-09
  With limited options to treat people with COVID-19, the U.S government has also secured millions of doses of Pfizer Inc's(PFE.N)rival antiviral drug, which last week was shown to cut by 89% the chance of hospitalization or death for adults at risk of severe disease.
  U.S. government to buy $1 billion more worth of Merck's COVID-19 pill
  Nov 9 (Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by
  U.S. government to buy $1 billion more worth of Merck's COVID-19 pill
  848 评论
  6
  分享
  举报
- 林欣霓林欣霓
  ·2021-11-03
  $KEPPEL DC REIT(AJBU.SI)$will increase position to average down to 2.40
  698 评论
  1
  分享
  举报
- 林欣霓林欣霓
  ·2021-11-03
  This 2day sudden shoot up? Any good news?
  517 评论
  2
  分享
  举报
- 林欣霓林欣霓
  ·2021-08-27
  Chip shortage will be a concern
  Can Tesla Shares Hit $900 Again This Year?
  Electric vehicle maker Tesla Motors' (NASDAQ:TSLA) stock is picking up momentum again. After falling
  Can Tesla Shares Hit $900 Again This Year?
  172 2
  6
  分享
  举报
- 林欣霓林欣霓
  ·2021-08-26
  Michael Burry vs Cathie Wood for win?
  非常抱歉，此主贴已删除
  95 2
  6
  分享
  举报
- 林欣霓林欣霓
  ·2021-08-25
  X//@林欣霓: Agree penny stock is high risk...
  Penny Stocks: Why You Should Always Stay Away
  Penny stocks – those stocks that trade for low prices, often with share prices of less than a dollar
  Penny Stocks: Why You Should Always Stay Away
  558 评论
  1
  分享
  举报
- 林欣霓林欣霓
  ·2021-08-22
  Agree penny stock is high risk...
  Penny Stocks: Why You Should Always Stay Away
  Penny stocks – those stocks that trade for low prices, often with share prices of less than a dollar
  Penny Stocks: Why You Should Always Stay Away
  231 评论
  6
  分享
  举报
- 林欣霓林欣霓
  ·2021-08-17
  The vaccine is still highly effective in people six months after their second dose. Yet there is some evidence its efficacy might diminish over longer periods, and the shot isn’t as effective againstt he Delta variant, prompting research into adding a third dose
  Pfizer, BioNTech Seek FDA Clearance for Covid-19 Booster
  Early-stage study shows third dose of vaccine offers a higher level of protection, companies say The
  Pfizer, BioNTech Seek FDA Clearance for Covid-19 Booster
  210 6
  6
  分享
  举报
- 林欣霓林欣霓
  ·2021-08-13
  Take 3rd dose for those weak immune system
  非常抱歉，此主贴已删除
  158 评论
  5
  分享
  举报

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3580168616843436","uuid":"3580168616843436","gmtCreate":1617085654174,"gmtModify":1622127892219,"name":"林欣霓","pinyin":"lxnlinxinni","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a28a5c6d65cfcd6a5024f3b15f4975e8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":19,"headSize":97,"tweetSize":44,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.08","exceedPercentage":"60.47%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.35%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":870828808,"gmtCreate":1636602784935,"gmtModify":1636602785083,"author":{"id":"3580168616843436","authorId":"3580168616843436","name":"林欣霓","avatar":"https://static.tigerbbs.com/a28a5c6d65cfcd6a5024f3b15f4975e8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580168616843436","idStr":"3580168616843436"},"themes":[],"htmlText":"Wood saids The next big 'Aha moment' for the market is when we see some success on [Tesla's] full self-driving autonomous front[微笑]&nbsp;","listText":"Wood saids The next big 'Aha moment' for the market is when we see some success on [Tesla's] full self-driving autonomous front[微笑]&nbsp;","text":"Wood saids The next big 'Aha moment' for the market is when we see some success on [Tesla's] full self-driving autonomous front[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/870828808","repostId":"2182005821","repostType":4,"isVote":1,"tweetType":1,"viewCount":960,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844774304,"gmtCreate":1636465227237,"gmtModify":1636467782146,"author":{"id":"3580168616843436","authorId":"3580168616843436","name":"林欣霓","avatar":"https://static.tigerbbs.com/a28a5c6d65cfcd6a5024f3b15f4975e8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580168616843436","idStr":"3580168616843436"},"themes":[],"htmlText":"With limited options to treat people with COVID-19, the U.S government has also secured millions of doses of Pfizer Inc's(PFE.N)rival antiviral drug, which last week was shown to cut by 89% the chance of hospitalization or death for adults at risk of severe disease.","listText":"With limited options to treat people with COVID-19, the U.S government has also secured millions of doses of Pfizer Inc's(PFE.N)rival antiviral drug, which last week was shown to cut by 89% the chance of hospitalization or death for adults at risk of severe disease.","text":"With limited options to treat people with COVID-19, the U.S government has also secured millions of doses of Pfizer Inc's(PFE.N)rival antiviral drug, which last week was shown to cut by 89% the chance of hospitalization or death for adults at risk of severe disease.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844774304","repostId":"1133150195","repostType":4,"repost":{"id":"1133150195","pubTimestamp":1636463600,"share":"https://www.laohu8.com/m/news/1133150195?lang=&edition=full","pubTime":"2021-11-09 21:13","market":"us","language":"en","title":"U.S. government to buy $1 billion more worth of Merck's COVID-19 pill","url":"https://stock-news.laohu8.com/highlight/detail?id=1133150195","media":"Reuters","summary":"Nov 9 (Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by","content":"<p>Nov 9 (Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck &amp; Co Inc(MRK.N)and partner Ridgeback Biotherapeutics, the companies said on Tuesday.</p>\n<p>The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.</p>\n<p>That brings the total secured courses to 3.1 million and worth $2.2 billion. Merck said the government has the right to buy 2 million more courses as part of the contract.</p>\n<p>The drug has been closely watched since data last month showed that when given early in the illness it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>\"Molnupiravir, if authorized, will be among the vaccines and medicines available to fight COVID-19 as part of our collective efforts to bring this pandemic to an end,\" said Frank Clyburn, president of Merck's human health business.</p>\n<p>With limited options to treat people with COVID-19, the U.S government has also secured millions of doses of Pfizer Inc's(PFE.N)rival antiviral drug, which last week was shown to cut by 89% the chance of hospitalization or death for adults at risk of severe disease.</p>\n<p>Merck's application with the U.S. Food and Drug Administration will be taken up by a panel of independent experts on Nov. 30, following which the regulator is expected to make a decision.</p>\n<p>Britain last week became the first country in the world to clear the use of molnupiravir.</p>\n<p>Merck expects to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.</p>\n<p>The drugmaker's shares rose nearly 1% to $83.41 in premarket trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. government to buy $1 billion more worth of Merck's COVID-19 pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. government to buy $1 billion more worth of Merck's COVID-19 pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-09 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/world/us/us-government-buy-14-mln-more-courses-mercks-covid-19-pill-2021-11-09/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 9 (Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc(MRK.N)and partner Ridgeback Biotherapeutics, the companies said on Tuesday.\nThe ...</p>\n\n<a href=\"https://www.reuters.com/world/us/us-government-buy-14-mln-more-courses-mercks-covid-19-pill-2021-11-09/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.reuters.com/world/us/us-government-buy-14-mln-more-courses-mercks-covid-19-pill-2021-11-09/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133150195","content_text":"Nov 9 (Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc(MRK.N)and partner Ridgeback Biotherapeutics, the companies said on Tuesday.\nThe government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.\nThat brings the total secured courses to 3.1 million and worth $2.2 billion. Merck said the government has the right to buy 2 million more courses as part of the contract.\nThe drug has been closely watched since data last month showed that when given early in the illness it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\n\"Molnupiravir, if authorized, will be among the vaccines and medicines available to fight COVID-19 as part of our collective efforts to bring this pandemic to an end,\" said Frank Clyburn, president of Merck's human health business.\nWith limited options to treat people with COVID-19, the U.S government has also secured millions of doses of Pfizer Inc's(PFE.N)rival antiviral drug, which last week was shown to cut by 89% the chance of hospitalization or death for adults at risk of severe disease.\nMerck's application with the U.S. Food and Drug Administration will be taken up by a panel of independent experts on Nov. 30, following which the regulator is expected to make a decision.\nBritain last week became the first country in the world to clear the use of molnupiravir.\nMerck expects to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.\nThe drugmaker's shares rose nearly 1% to $83.41 in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":848,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841212454,"gmtCreate":1635914353891,"gmtModify":1635914354043,"author":{"id":"3580168616843436","authorId":"3580168616843436","name":"林欣霓","avatar":"https://static.tigerbbs.com/a28a5c6d65cfcd6a5024f3b15f4975e8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580168616843436","idStr":"3580168616843436"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AJBU.SI\">$KEPPEL DC REIT(AJBU.SI)$</a>will increase position to average down to 2.40","listText":"<a href=\"https://laohu8.com/S/AJBU.SI\">$KEPPEL DC REIT(AJBU.SI)$</a>will increase position to average down to 2.40","text":"$KEPPEL DC REIT(AJBU.SI)$will increase position to average down to 2.40","images":[{"img":"https://static.tigerbbs.com/1f56f9ef2bf442a89a6b1c99a97554db","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/841212454","isVote":1,"tweetType":1,"viewCount":698,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841218712,"gmtCreate":1635914168365,"gmtModify":1635914168473,"author":{"id":"3580168616843436","authorId":"3580168616843436","name":"林欣霓","avatar":"https://static.tigerbbs.com/a28a5c6d65cfcd6a5024f3b15f4975e8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580168616843436","idStr":"3580168616843436"},"themes":[],"htmlText":"This 2day sudden shoot up? Any good news?&nbsp;","listText":"This 2day sudden shoot up? Any good news?&nbsp;","text":"This 2day sudden shoot up? Any good news?","images":[{"img":"https://static.tigerbbs.com/8636f4ef436550a97b1bd44349d18c4f","width":"1080","height":"3444"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841218712","isVote":1,"tweetType":1,"viewCount":517,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":810788474,"gmtCreate":1630016254298,"gmtModify":1704954503604,"author":{"id":"3580168616843436","authorId":"3580168616843436","name":"林欣霓","avatar":"https://static.tigerbbs.com/a28a5c6d65cfcd6a5024f3b15f4975e8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580168616843436","idStr":"3580168616843436"},"themes":[],"htmlText":"Chip shortage will be a concern","listText":"Chip shortage will be a concern","text":"Chip shortage will be a concern","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/810788474","repostId":"1161561973","repostType":4,"repost":{"id":"1161561973","pubTimestamp":1629991651,"share":"https://www.laohu8.com/m/news/1161561973?lang=&edition=full","pubTime":"2021-08-26 23:27","market":"us","language":"en","title":"Can Tesla Shares Hit $900 Again This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=1161561973","media":"investing.com","summary":"Electric vehicle maker Tesla Motors' (NASDAQ:TSLA) stock is picking up momentum again. After falling","content":"<p>Electric vehicle maker <a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a>' (NASDAQ:TSLA) stock is picking up momentum again. After falling from a record high $900.40, hit intraday on Jan. 25, TSLA shares have gained 17% during the past three months, outperforming the benchmark&nbsp;NASDAQ 100&nbsp;Index.</p>\n<p>The biggest question Tesla bulls now have is, whether, on top of the current gains, can the EV manufacturer's stock push through back to the all-time high of $900 this year?</p>\n<p><img src=\"https://static.tigerbbs.com/b4b9078f00190f208dd63b32c4f617c6\" tg-width=\"651\" tg-height=\"708\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Tesla Weekly Chart.</p>\n<p>Given the highly volatile nature of the stock, it’s tough to predict whether the current Tesla rally has legs. But it’s important to note that the outlook for its car sales is becoming more uncertain than it was a year ago.</p>\n<p>First, the global chip shortage continues to cast doubt on Tesla’s ambitious sales targets for 2021. Chief Executive Officer Elon Musk highlighted challenges that come from the unpredictability of chip supplies and the hurdles he expects in ramping production at two new factories in Austin, Texas, and Berlin, later this year.</p>\n<p>Tesla again delayed delivery of its semi-trailer truck—already two years late. The first trucks of this type are now slated for 2022. The company attributed the delay to supply-chain issues and limited battery-cell supply, as well as management trying to focus on getting new factories online. The company’s plans for its first pickup truck, once expected to go to customers as early as this year, are also being affected by parts issues.</p>\n<p>This is what Musk told analysts last month:</p>\n<blockquote>\n “While we’re making cars at full speed, the global chip-shortage situation remains quite serious. For the rest of this year, our growth rate will be determined by the slowest part in our supply chain.”\n</blockquote>\n<p>Regulatory Probe</p>\n<p>Besides the risks to the market’s earnings consensus for this fiscal year, Tesla is facing a regulatory probe that could result in a massive recall.</p>\n<p>The U.S.opened a formal investigation&nbsp;into Tesla’s Autopilot system last week after almost a dozen collisions involving first-responder vehicles. In the last seven years, Tesla has charged clients thousands of dollars for this feature.</p>\n<p>The probe by the National Highway Traffic Safety Administration (NHTSA) covers an estimated 765,000 Tesla Model Y, X, S and 3 vehicles from the 2014 model year onward. The regulator—which has the power to deem cars defective and order recalls—said&nbsp;it launched the investigation after 11 crashes that resulted in 17 injuries and one fatality.</p>\n<p>Bloomberg reported&nbsp;that Tesla has been criticized for years for labeling the system in a potentially misleading way. Since late 2016, it has marketed this higher-level functionality feature as Full Self-Driving Capability. In reality, Autopilot is a driver-assistance system that maintains vehicles’ speed and keeps them centered in lanes when engaged, though the driver is supposed to supervise at all times.</p>\n<p>Tesla now sells that package of features—often referred to as FSD—for $10,000 or $199 a month.</p>\n<p>After the NHTSA launched of the probe, two Democratic senators asked the Federal Trade Commission to also investigate Tesla over the company’s advertising of its Autopilot and FSD technology.</p>\n<p>In a&nbsp;letter&nbsp;last Wednesday, Sen. Richard Blumenthal of Connecticut and Sen. Ed Markey of Massachusetts asked FTC Chair Lina Khan to examine whether Tesla used “potentially deceptive and unfair practices” in its marketing of those technologies.</p>\n<p>“We fear that Tesla’s Autopilot and FSD features are not as mature and reliable as the company pitches to the public,” they wrote, pointing to comments from Musk, as well as a 2019 YouTube video entitled “Full Self-Driving” and has a link to Tesla’s site.</p>\n<p>Highlighting these risks and how they could affect Tesla’s current stock price, however, shouldn’t hide the fact that there are many analysts who continue to remain bullish on TSLA. Piper Sandler reiterated its overweight rating on the stock and its price target of $1,200 this month.</p>\n<p>In a note, analysts Alexander Potter and Winnie Dong said:</p>\n<blockquote>\n “Bottom line: We still really like this stock. Tesla is still the driving force behind higher [battery electric vehicle] penetration globally.”\n</blockquote>\n<p><b>Bottom Line</b></p>\n<p>It’s difficult to predict the future course for Tesla stock given the huge amount of speculative interest in this name. But recent developments show that it will be quite hard for the EV automaker to exceed expectations in this tough manufacturing environment.</p>\n<p>Investors should trade this name with caution.</p>","source":"lsy1594375853987","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Tesla Shares Hit $900 Again This Year? </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Tesla Shares Hit $900 Again This Year? \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 23:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investing.com/analysis/can-tesla-shares-hit-900-again-this-year-200599999><strong>investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Electric vehicle maker Tesla Motors' (NASDAQ:TSLA) stock is picking up momentum again. After falling from a record high $900.40, hit intraday on Jan. 25, TSLA shares have gained 17% during the past ...</p>\n\n<a href=\"https://www.investing.com/analysis/can-tesla-shares-hit-900-again-this-year-200599999\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.investing.com/analysis/can-tesla-shares-hit-900-again-this-year-200599999","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161561973","content_text":"Electric vehicle maker Tesla Motors' (NASDAQ:TSLA) stock is picking up momentum again. After falling from a record high $900.40, hit intraday on Jan. 25, TSLA shares have gained 17% during the past three months, outperforming the benchmark NASDAQ 100 Index.\nThe biggest question Tesla bulls now have is, whether, on top of the current gains, can the EV manufacturer's stock push through back to the all-time high of $900 this year?\nTesla Weekly Chart.\nGiven the highly volatile nature of the stock, it’s tough to predict whether the current Tesla rally has legs. But it’s important to note that the outlook for its car sales is becoming more uncertain than it was a year ago.\nFirst, the global chip shortage continues to cast doubt on Tesla’s ambitious sales targets for 2021. Chief Executive Officer Elon Musk highlighted challenges that come from the unpredictability of chip supplies and the hurdles he expects in ramping production at two new factories in Austin, Texas, and Berlin, later this year.\nTesla again delayed delivery of its semi-trailer truck—already two years late. The first trucks of this type are now slated for 2022. The company attributed the delay to supply-chain issues and limited battery-cell supply, as well as management trying to focus on getting new factories online. The company’s plans for its first pickup truck, once expected to go to customers as early as this year, are also being affected by parts issues.\nThis is what Musk told analysts last month:\n\n “While we’re making cars at full speed, the global chip-shortage situation remains quite serious. For the rest of this year, our growth rate will be determined by the slowest part in our supply chain.”\n\nRegulatory Probe\nBesides the risks to the market’s earnings consensus for this fiscal year, Tesla is facing a regulatory probe that could result in a massive recall.\nThe U.S.opened a formal investigation into Tesla’s Autopilot system last week after almost a dozen collisions involving first-responder vehicles. In the last seven years, Tesla has charged clients thousands of dollars for this feature.\nThe probe by the National Highway Traffic Safety Administration (NHTSA) covers an estimated 765,000 Tesla Model Y, X, S and 3 vehicles from the 2014 model year onward. The regulator—which has the power to deem cars defective and order recalls—said it launched the investigation after 11 crashes that resulted in 17 injuries and one fatality.\nBloomberg reported that Tesla has been criticized for years for labeling the system in a potentially misleading way. Since late 2016, it has marketed this higher-level functionality feature as Full Self-Driving Capability. In reality, Autopilot is a driver-assistance system that maintains vehicles’ speed and keeps them centered in lanes when engaged, though the driver is supposed to supervise at all times.\nTesla now sells that package of features—often referred to as FSD—for $10,000 or $199 a month.\nAfter the NHTSA launched of the probe, two Democratic senators asked the Federal Trade Commission to also investigate Tesla over the company’s advertising of its Autopilot and FSD technology.\nIn a letter last Wednesday, Sen. Richard Blumenthal of Connecticut and Sen. Ed Markey of Massachusetts asked FTC Chair Lina Khan to examine whether Tesla used “potentially deceptive and unfair practices” in its marketing of those technologies.\n“We fear that Tesla’s Autopilot and FSD features are not as mature and reliable as the company pitches to the public,” they wrote, pointing to comments from Musk, as well as a 2019 YouTube video entitled “Full Self-Driving” and has a link to Tesla’s site.\nHighlighting these risks and how they could affect Tesla’s current stock price, however, shouldn’t hide the fact that there are many analysts who continue to remain bullish on TSLA. Piper Sandler reiterated its overweight rating on the stock and its price target of $1,200 this month.\nIn a note, analysts Alexander Potter and Winnie Dong said:\n\n “Bottom line: We still really like this stock. Tesla is still the driving force behind higher [battery electric vehicle] penetration globally.”\n\nBottom Line\nIt’s difficult to predict the future course for Tesla stock given the huge amount of speculative interest in this name. But recent developments show that it will be quite hard for the EV automaker to exceed expectations in this tough manufacturing environment.\nInvestors should trade this name with caution.","news_type":1},"isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810192870,"gmtCreate":1629950009190,"gmtModify":1631883959055,"author":{"id":"3580168616843436","authorId":"3580168616843436","name":"林欣霓","avatar":"https://static.tigerbbs.com/a28a5c6d65cfcd6a5024f3b15f4975e8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580168616843436","idStr":"3580168616843436"},"themes":[],"htmlText":"Michael Burry vs Cathie Wood for win?&nbsp;","listText":"Michael Burry vs Cathie Wood for win?&nbsp;","text":"Michael Burry vs Cathie Wood for win?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/810192870","repostId":"1101434650","repostType":4,"isVote":1,"tweetType":1,"viewCount":95,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837072249,"gmtCreate":1629850527381,"gmtModify":1631888076526,"author":{"id":"3580168616843436","authorId":"3580168616843436","name":"林欣霓","avatar":"https://static.tigerbbs.com/a28a5c6d65cfcd6a5024f3b15f4975e8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580168616843436","idStr":"3580168616843436"},"themes":[],"htmlText":"X//<a href=\"https://laohu8.com/U/3580168616843436\">@林欣霓</a>: Agree penny stock is high risk...&nbsp;","listText":"X//<a href=\"https://laohu8.com/U/3580168616843436\">@林欣霓</a>: Agree penny stock is high risk...&nbsp;","text":"X//@林欣霓: Agree penny stock is high risk...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/837072249","repostId":"1172699620","repostType":4,"repost":{"id":"1172699620","pubTimestamp":1629450202,"share":"https://www.laohu8.com/m/news/1172699620?lang=&edition=full","pubTime":"2021-08-20 17:03","market":"us","language":"en","title":"Penny Stocks: Why You Should Always Stay Away","url":"https://stock-news.laohu8.com/highlight/detail?id=1172699620","media":"Kiplinger","summary":"Penny stocks – those stocks that trade for low prices, often with share prices of less than a dollar","content":"<p>Penny stocks – those stocks that trade for low prices, often with share prices of less than a dollar per share – are dangerous. Period. Indeed, with a few exceptions, investors should steer clear of these uber-cheap stocks, which typically trade over-the-counter and not on a major exchange.</p>\n<p>Call them penny stocks, microcaps or OTC stocks; by any name, they’re bad news. Promises of quick and easy riches are easier to fall for when an investment can be made with so little money up front. An investor might think, \"How risky could it be?\"</p>\n<p>Plenty. Per the Securities and Exchange Commission: “Academic studies find that OTC stocks tend to be highly illiquid; are frequent targets of alleged market manipulation; generate negative and volatile investment returns on average; and rarely grow into a large company or transition to listing on a stock exchange.”</p>\n<p>We’ll break down what all that means below, but suffice to say, the SEC is not a fan.</p>\n<h3><b>Why Penny Stocks Are So Dangerous</b></h3>\n<p>To be clear, this is not to say that every penny stock or OTC company is a scam. The danger is that the over-the-counter market is where the scam stocks live. Think of it as a bad neighborhood. Being there can make you a mark for a con.</p>\n<p>For some background, the OTC market is different from exchanges like the New York Stock Exchange or Nasdaq, where trading is centralized. There is no one OTC exchange. Instead, the OTC connects buyers and sellers over a computer- and telephone-based system. Any stock that does not trade on the NYSE, Nasdaq or other established U.S. exchange can trade over-the-counter. These securities also are known as “unlisted stocks.”</p>\n<p>Typically, OTC stocks tend to be highly risky microcap stocks (the shares of small companies with market capitalizations of under $300 million), which include nanocap stocks (those with market values of under $50 million).</p>\n<p>The SEC has long warned investors about the high risks associated with such stocks. The Financial Industry Regulatory Authority (FINRA), the industry’s self-regulatory agency, likewise waves a red flag over the buying and trading of OTC securities.</p>\n<p>That’s because companies that list on the OTC aren’t required to file periodic or audited financial reports as they must do if they are listed on a major exchange, such as the NYSE or the Nasdaq. In other words, there’s no way to know if they’re telling the truth when they claim to have sales and profits. The major exchanges also have listing requirements; OTC stocks don’t. For example, a company must have at least 400 shareholders and a market value of at least $40 million to get a listing on the New York Stock Exchange. The OTC makes no such requirements.</p>\n<p>Put it all together, and it makes it easier for unscrupulous managers to lie about their business prospects or commit securities fraud.</p>\n<p>But that’s not all. The shares that exchange hands on the OTC tend to be “illiquid,” meaning they often trade in low volumes and have a limited number of buyers and sellers. That can make it difficult or impossible for investors to buy or sell shares at the prices they want.</p>\n<p>That lack of liquidity also makes many OTC stocks the perfect vehicle for “pump-and-dump” schemes where stock promoters lure investors to buy shares, increasing the stock price. Then, when the price gets high enough, the pumper sells his shares, causing the stock to fall and leaving investors with poor returns, or even losses. Anyone here see&nbsp;<i>The Wolf of Wall Street</i>?</p>\n<p>To protect investors from falling for these schemes, the SEC suspended trading of more than 800 microcap stocks – more than 8% of the OTC market – between 2012 and 2015. Once a stock has been suspended from trading, it cannot be relisted unless the company provides updated financial information to prove it’s actually operational. Since that rarely happens, trading suspensions essentially render the shares useless to scam artists.</p>\n<h3><b>Legitimate OTCs</b></h3>\n<p>Be that as it may, there is one segment of the OTC market that investors need not fear.</p>\n<p>Amidst the riff-raff, some of the biggest, most respected foreign companies in the world list their U.S. shares over-the-counter instead of on the major U.S. exchanges. Here, you’ll find shares of&nbsp;<b>The <a href=\"https://laohu8.com/S/IDCBY\">Industrial and Commercial Bank of China Ltd.</a></b>&nbsp;(IDCBY), which happens to be the biggest bank in the world. You also can buy shares of Switzerland’s<b>Nestlé</b>(NSRGY), the largest food company in the world; China’s&nbsp;<b><a href=\"https://laohu8.com/S/TCEHY\">Tencent Holding Ltd.</a></b>&nbsp;(TCEHY), one of the country’s largest internet service providers; and Japanese gaming giant&nbsp;<b><a href=\"https://laohu8.com/S/NTDOY\">Nintendo Co., Ltd.</a> </b>(NTDOY).</p>\n<p>Why would major, international publicly traded companies rub shoulders with firms that issue highly speculative penny stocks?</p>\n<p>The reason has to do with cost and convenience. For example, a foreign firm listing on the NYSE or Nasdaq must prepare two sets of audited financial statements for everything it does – one to conform with international accounting standards, and another that adheres to the generally accepted accounting principles (GAAP) used in the U.S. That isn’t a requirement over-the-counter.</p>\n<p>With an OTC listing, a foreign company gains access to the vast pool of U.S. equity investors at a fraction of the cost and effort.</p>\n<p>The bottom line is that with the exception of large, established foreign firms, OTC stocks come with too many risks. It’s not possible for the average investor to know if the company is on the up and up. And even legitimate tiny companies can fail virtually overnight. The pitfalls of trading OTC stocks just aren’t worth it.</p>\n<p>It’s easy enough to lose money investing in stocks. Why make it easier?</p>","source":"lsy1629449927514","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Penny Stocks: Why You Should Always Stay Away</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPenny Stocks: Why You Should Always Stay Away\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 17:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.kiplinger.com/investing/603303/penny-stocks-always-stay-away><strong>Kiplinger</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Penny stocks – those stocks that trade for low prices, often with share prices of less than a dollar per share – are dangerous. Period. Indeed, with a few exceptions, investors should steer clear of ...</p>\n\n<a href=\"https://www.kiplinger.com/investing/603303/penny-stocks-always-stay-away\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TCEHY":"腾讯控股ADR","NTDOY":"任天堂","IDCBY":"工商银行ADR"},"source_url":"https://www.kiplinger.com/investing/603303/penny-stocks-always-stay-away","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172699620","content_text":"Penny stocks – those stocks that trade for low prices, often with share prices of less than a dollar per share – are dangerous. Period. Indeed, with a few exceptions, investors should steer clear of these uber-cheap stocks, which typically trade over-the-counter and not on a major exchange.\nCall them penny stocks, microcaps or OTC stocks; by any name, they’re bad news. Promises of quick and easy riches are easier to fall for when an investment can be made with so little money up front. An investor might think, \"How risky could it be?\"\nPlenty. Per the Securities and Exchange Commission: “Academic studies find that OTC stocks tend to be highly illiquid; are frequent targets of alleged market manipulation; generate negative and volatile investment returns on average; and rarely grow into a large company or transition to listing on a stock exchange.”\nWe’ll break down what all that means below, but suffice to say, the SEC is not a fan.\nWhy Penny Stocks Are So Dangerous\nTo be clear, this is not to say that every penny stock or OTC company is a scam. The danger is that the over-the-counter market is where the scam stocks live. Think of it as a bad neighborhood. Being there can make you a mark for a con.\nFor some background, the OTC market is different from exchanges like the New York Stock Exchange or Nasdaq, where trading is centralized. There is no one OTC exchange. Instead, the OTC connects buyers and sellers over a computer- and telephone-based system. Any stock that does not trade on the NYSE, Nasdaq or other established U.S. exchange can trade over-the-counter. These securities also are known as “unlisted stocks.”\nTypically, OTC stocks tend to be highly risky microcap stocks (the shares of small companies with market capitalizations of under $300 million), which include nanocap stocks (those with market values of under $50 million).\nThe SEC has long warned investors about the high risks associated with such stocks. The Financial Industry Regulatory Authority (FINRA), the industry’s self-regulatory agency, likewise waves a red flag over the buying and trading of OTC securities.\nThat’s because companies that list on the OTC aren’t required to file periodic or audited financial reports as they must do if they are listed on a major exchange, such as the NYSE or the Nasdaq. In other words, there’s no way to know if they’re telling the truth when they claim to have sales and profits. The major exchanges also have listing requirements; OTC stocks don’t. For example, a company must have at least 400 shareholders and a market value of at least $40 million to get a listing on the New York Stock Exchange. The OTC makes no such requirements.\nPut it all together, and it makes it easier for unscrupulous managers to lie about their business prospects or commit securities fraud.\nBut that’s not all. The shares that exchange hands on the OTC tend to be “illiquid,” meaning they often trade in low volumes and have a limited number of buyers and sellers. That can make it difficult or impossible for investors to buy or sell shares at the prices they want.\nThat lack of liquidity also makes many OTC stocks the perfect vehicle for “pump-and-dump” schemes where stock promoters lure investors to buy shares, increasing the stock price. Then, when the price gets high enough, the pumper sells his shares, causing the stock to fall and leaving investors with poor returns, or even losses. Anyone here see The Wolf of Wall Street?\nTo protect investors from falling for these schemes, the SEC suspended trading of more than 800 microcap stocks – more than 8% of the OTC market – between 2012 and 2015. Once a stock has been suspended from trading, it cannot be relisted unless the company provides updated financial information to prove it’s actually operational. Since that rarely happens, trading suspensions essentially render the shares useless to scam artists.\nLegitimate OTCs\nBe that as it may, there is one segment of the OTC market that investors need not fear.\nAmidst the riff-raff, some of the biggest, most respected foreign companies in the world list their U.S. shares over-the-counter instead of on the major U.S. exchanges. Here, you’ll find shares of The Industrial and Commercial Bank of China Ltd. (IDCBY), which happens to be the biggest bank in the world. You also can buy shares of Switzerland’sNestlé(NSRGY), the largest food company in the world; China’s Tencent Holding Ltd. (TCEHY), one of the country’s largest internet service providers; and Japanese gaming giant Nintendo Co., Ltd. (NTDOY).\nWhy would major, international publicly traded companies rub shoulders with firms that issue highly speculative penny stocks?\nThe reason has to do with cost and convenience. For example, a foreign firm listing on the NYSE or Nasdaq must prepare two sets of audited financial statements for everything it does – one to conform with international accounting standards, and another that adheres to the generally accepted accounting principles (GAAP) used in the U.S. That isn’t a requirement over-the-counter.\nWith an OTC listing, a foreign company gains access to the vast pool of U.S. equity investors at a fraction of the cost and effort.\nThe bottom line is that with the exception of large, established foreign firms, OTC stocks come with too many risks. It’s not possible for the average investor to know if the company is on the up and up. And even legitimate tiny companies can fail virtually overnight. The pitfalls of trading OTC stocks just aren’t worth it.\nIt’s easy enough to lose money investing in stocks. Why make it easier?","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":832181826,"gmtCreate":1629598305065,"gmtModify":1631888076539,"author":{"id":"3580168616843436","authorId":"3580168616843436","name":"林欣霓","avatar":"https://static.tigerbbs.com/a28a5c6d65cfcd6a5024f3b15f4975e8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580168616843436","idStr":"3580168616843436"},"themes":[],"htmlText":"Agree penny stock is high risk...&nbsp;","listText":"Agree penny stock is high risk...&nbsp;","text":"Agree penny stock is high risk...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/832181826","repostId":"1172699620","repostType":4,"repost":{"id":"1172699620","pubTimestamp":1629450202,"share":"https://www.laohu8.com/m/news/1172699620?lang=&edition=full","pubTime":"2021-08-20 17:03","market":"us","language":"en","title":"Penny Stocks: Why You Should Always Stay Away","url":"https://stock-news.laohu8.com/highlight/detail?id=1172699620","media":"Kiplinger","summary":"Penny stocks – those stocks that trade for low prices, often with share prices of less than a dollar","content":"<p>Penny stocks – those stocks that trade for low prices, often with share prices of less than a dollar per share – are dangerous. Period. Indeed, with a few exceptions, investors should steer clear of these uber-cheap stocks, which typically trade over-the-counter and not on a major exchange.</p>\n<p>Call them penny stocks, microcaps or OTC stocks; by any name, they’re bad news. Promises of quick and easy riches are easier to fall for when an investment can be made with so little money up front. An investor might think, \"How risky could it be?\"</p>\n<p>Plenty. Per the Securities and Exchange Commission: “Academic studies find that OTC stocks tend to be highly illiquid; are frequent targets of alleged market manipulation; generate negative and volatile investment returns on average; and rarely grow into a large company or transition to listing on a stock exchange.”</p>\n<p>We’ll break down what all that means below, but suffice to say, the SEC is not a fan.</p>\n<h3><b>Why Penny Stocks Are So Dangerous</b></h3>\n<p>To be clear, this is not to say that every penny stock or OTC company is a scam. The danger is that the over-the-counter market is where the scam stocks live. Think of it as a bad neighborhood. Being there can make you a mark for a con.</p>\n<p>For some background, the OTC market is different from exchanges like the New York Stock Exchange or Nasdaq, where trading is centralized. There is no one OTC exchange. Instead, the OTC connects buyers and sellers over a computer- and telephone-based system. Any stock that does not trade on the NYSE, Nasdaq or other established U.S. exchange can trade over-the-counter. These securities also are known as “unlisted stocks.”</p>\n<p>Typically, OTC stocks tend to be highly risky microcap stocks (the shares of small companies with market capitalizations of under $300 million), which include nanocap stocks (those with market values of under $50 million).</p>\n<p>The SEC has long warned investors about the high risks associated with such stocks. The Financial Industry Regulatory Authority (FINRA), the industry’s self-regulatory agency, likewise waves a red flag over the buying and trading of OTC securities.</p>\n<p>That’s because companies that list on the OTC aren’t required to file periodic or audited financial reports as they must do if they are listed on a major exchange, such as the NYSE or the Nasdaq. In other words, there’s no way to know if they’re telling the truth when they claim to have sales and profits. The major exchanges also have listing requirements; OTC stocks don’t. For example, a company must have at least 400 shareholders and a market value of at least $40 million to get a listing on the New York Stock Exchange. The OTC makes no such requirements.</p>\n<p>Put it all together, and it makes it easier for unscrupulous managers to lie about their business prospects or commit securities fraud.</p>\n<p>But that’s not all. The shares that exchange hands on the OTC tend to be “illiquid,” meaning they often trade in low volumes and have a limited number of buyers and sellers. That can make it difficult or impossible for investors to buy or sell shares at the prices they want.</p>\n<p>That lack of liquidity also makes many OTC stocks the perfect vehicle for “pump-and-dump” schemes where stock promoters lure investors to buy shares, increasing the stock price. Then, when the price gets high enough, the pumper sells his shares, causing the stock to fall and leaving investors with poor returns, or even losses. Anyone here see&nbsp;<i>The Wolf of Wall Street</i>?</p>\n<p>To protect investors from falling for these schemes, the SEC suspended trading of more than 800 microcap stocks – more than 8% of the OTC market – between 2012 and 2015. Once a stock has been suspended from trading, it cannot be relisted unless the company provides updated financial information to prove it’s actually operational. Since that rarely happens, trading suspensions essentially render the shares useless to scam artists.</p>\n<h3><b>Legitimate OTCs</b></h3>\n<p>Be that as it may, there is one segment of the OTC market that investors need not fear.</p>\n<p>Amidst the riff-raff, some of the biggest, most respected foreign companies in the world list their U.S. shares over-the-counter instead of on the major U.S. exchanges. Here, you’ll find shares of&nbsp;<b>The <a href=\"https://laohu8.com/S/IDCBY\">Industrial and Commercial Bank of China Ltd.</a></b>&nbsp;(IDCBY), which happens to be the biggest bank in the world. You also can buy shares of Switzerland’s<b>Nestlé</b>(NSRGY), the largest food company in the world; China’s&nbsp;<b><a href=\"https://laohu8.com/S/TCEHY\">Tencent Holding Ltd.</a></b>&nbsp;(TCEHY), one of the country’s largest internet service providers; and Japanese gaming giant&nbsp;<b><a href=\"https://laohu8.com/S/NTDOY\">Nintendo Co., Ltd.</a> </b>(NTDOY).</p>\n<p>Why would major, international publicly traded companies rub shoulders with firms that issue highly speculative penny stocks?</p>\n<p>The reason has to do with cost and convenience. For example, a foreign firm listing on the NYSE or Nasdaq must prepare two sets of audited financial statements for everything it does – one to conform with international accounting standards, and another that adheres to the generally accepted accounting principles (GAAP) used in the U.S. That isn’t a requirement over-the-counter.</p>\n<p>With an OTC listing, a foreign company gains access to the vast pool of U.S. equity investors at a fraction of the cost and effort.</p>\n<p>The bottom line is that with the exception of large, established foreign firms, OTC stocks come with too many risks. It’s not possible for the average investor to know if the company is on the up and up. And even legitimate tiny companies can fail virtually overnight. The pitfalls of trading OTC stocks just aren’t worth it.</p>\n<p>It’s easy enough to lose money investing in stocks. Why make it easier?</p>","source":"lsy1629449927514","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Penny Stocks: Why You Should Always Stay Away</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPenny Stocks: Why You Should Always Stay Away\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 17:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.kiplinger.com/investing/603303/penny-stocks-always-stay-away><strong>Kiplinger</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Penny stocks – those stocks that trade for low prices, often with share prices of less than a dollar per share – are dangerous. Period. Indeed, with a few exceptions, investors should steer clear of ...</p>\n\n<a href=\"https://www.kiplinger.com/investing/603303/penny-stocks-always-stay-away\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TCEHY":"腾讯控股ADR","NTDOY":"任天堂","IDCBY":"工商银行ADR"},"source_url":"https://www.kiplinger.com/investing/603303/penny-stocks-always-stay-away","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172699620","content_text":"Penny stocks – those stocks that trade for low prices, often with share prices of less than a dollar per share – are dangerous. Period. Indeed, with a few exceptions, investors should steer clear of these uber-cheap stocks, which typically trade over-the-counter and not on a major exchange.\nCall them penny stocks, microcaps or OTC stocks; by any name, they’re bad news. Promises of quick and easy riches are easier to fall for when an investment can be made with so little money up front. An investor might think, \"How risky could it be?\"\nPlenty. Per the Securities and Exchange Commission: “Academic studies find that OTC stocks tend to be highly illiquid; are frequent targets of alleged market manipulation; generate negative and volatile investment returns on average; and rarely grow into a large company or transition to listing on a stock exchange.”\nWe’ll break down what all that means below, but suffice to say, the SEC is not a fan.\nWhy Penny Stocks Are So Dangerous\nTo be clear, this is not to say that every penny stock or OTC company is a scam. The danger is that the over-the-counter market is where the scam stocks live. Think of it as a bad neighborhood. Being there can make you a mark for a con.\nFor some background, the OTC market is different from exchanges like the New York Stock Exchange or Nasdaq, where trading is centralized. There is no one OTC exchange. Instead, the OTC connects buyers and sellers over a computer- and telephone-based system. Any stock that does not trade on the NYSE, Nasdaq or other established U.S. exchange can trade over-the-counter. These securities also are known as “unlisted stocks.”\nTypically, OTC stocks tend to be highly risky microcap stocks (the shares of small companies with market capitalizations of under $300 million), which include nanocap stocks (those with market values of under $50 million).\nThe SEC has long warned investors about the high risks associated with such stocks. The Financial Industry Regulatory Authority (FINRA), the industry’s self-regulatory agency, likewise waves a red flag over the buying and trading of OTC securities.\nThat’s because companies that list on the OTC aren’t required to file periodic or audited financial reports as they must do if they are listed on a major exchange, such as the NYSE or the Nasdaq. In other words, there’s no way to know if they’re telling the truth when they claim to have sales and profits. The major exchanges also have listing requirements; OTC stocks don’t. For example, a company must have at least 400 shareholders and a market value of at least $40 million to get a listing on the New York Stock Exchange. The OTC makes no such requirements.\nPut it all together, and it makes it easier for unscrupulous managers to lie about their business prospects or commit securities fraud.\nBut that’s not all. The shares that exchange hands on the OTC tend to be “illiquid,” meaning they often trade in low volumes and have a limited number of buyers and sellers. That can make it difficult or impossible for investors to buy or sell shares at the prices they want.\nThat lack of liquidity also makes many OTC stocks the perfect vehicle for “pump-and-dump” schemes where stock promoters lure investors to buy shares, increasing the stock price. Then, when the price gets high enough, the pumper sells his shares, causing the stock to fall and leaving investors with poor returns, or even losses. Anyone here see The Wolf of Wall Street?\nTo protect investors from falling for these schemes, the SEC suspended trading of more than 800 microcap stocks – more than 8% of the OTC market – between 2012 and 2015. Once a stock has been suspended from trading, it cannot be relisted unless the company provides updated financial information to prove it’s actually operational. Since that rarely happens, trading suspensions essentially render the shares useless to scam artists.\nLegitimate OTCs\nBe that as it may, there is one segment of the OTC market that investors need not fear.\nAmidst the riff-raff, some of the biggest, most respected foreign companies in the world list their U.S. shares over-the-counter instead of on the major U.S. exchanges. Here, you’ll find shares of The Industrial and Commercial Bank of China Ltd. (IDCBY), which happens to be the biggest bank in the world. You also can buy shares of Switzerland’sNestlé(NSRGY), the largest food company in the world; China’s Tencent Holding Ltd. (TCEHY), one of the country’s largest internet service providers; and Japanese gaming giant Nintendo Co., Ltd. (NTDOY).\nWhy would major, international publicly traded companies rub shoulders with firms that issue highly speculative penny stocks?\nThe reason has to do with cost and convenience. For example, a foreign firm listing on the NYSE or Nasdaq must prepare two sets of audited financial statements for everything it does – one to conform with international accounting standards, and another that adheres to the generally accepted accounting principles (GAAP) used in the U.S. That isn’t a requirement over-the-counter.\nWith an OTC listing, a foreign company gains access to the vast pool of U.S. equity investors at a fraction of the cost and effort.\nThe bottom line is that with the exception of large, established foreign firms, OTC stocks come with too many risks. It’s not possible for the average investor to know if the company is on the up and up. And even legitimate tiny companies can fail virtually overnight. The pitfalls of trading OTC stocks just aren’t worth it.\nIt’s easy enough to lose money investing in stocks. Why make it easier?","news_type":1},"isVote":1,"tweetType":1,"viewCount":231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839643303,"gmtCreate":1629158484302,"gmtModify":1631888076553,"author":{"id":"3580168616843436","authorId":"3580168616843436","name":"林欣霓","avatar":"https://static.tigerbbs.com/a28a5c6d65cfcd6a5024f3b15f4975e8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580168616843436","idStr":"3580168616843436"},"themes":[],"htmlText":"The vaccine is still highly effective in people six months after their second dose. Yet there is some evidence its efficacy might diminish over longer periods, and the shot isn’t as effective againstt he Delta variant, prompting research into adding a third dose","listText":"The vaccine is still highly effective in people six months after their second dose. Yet there is some evidence its efficacy might diminish over longer periods, and the shot isn’t as effective againstt he Delta variant, prompting research into adding a third dose","text":"The vaccine is still highly effective in people six months after their second dose. Yet there is some evidence its efficacy might diminish over longer periods, and the shot isn’t as effective againstt he Delta variant, prompting research into adding a third dose","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/839643303","repostId":"1166738043","repostType":4,"repost":{"id":"1166738043","pubTimestamp":1629158127,"share":"https://www.laohu8.com/m/news/1166738043?lang=&edition=full","pubTime":"2021-08-17 07:55","market":"us","language":"en","title":"Pfizer, BioNTech Seek FDA Clearance for Covid-19 Booster","url":"https://stock-news.laohu8.com/highlight/detail?id=1166738043","media":"The Wall Street Journal","summary":"Early-stage study shows third dose of vaccine offers a higher level of protection, companies say\nThe","content":"<p>Early-stage study shows third dose of vaccine offers a higher level of protection, companies say</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/14a5e62531f6fe58f57ee8f19db73a40\" tg-width=\"860\" tg-height=\"573\" width=\"100%\" height=\"auto\"><span>The addition of a third dose appeared safe, Pfizer and BioNTech said. A Covid-19 vaccination at a Schwenksville, Pa., pharmacy.</span></p>\n<p>Pfizer&nbsp;Inc.&nbsp;and partner&nbsp;BioNTech SE&nbsp;have submitted data to U.S. health regulators needed to cleara Covid-19 booster shot among the general public.</p>\n<p>The companies said Monday they sent to the U.S. Food and Drug Administration results from a small, early-stage study showing a third dose of their vaccine generated higher levels of neutralizing antibodies against the original virus and against the Beta and Delta variants than the standard two-dose regimen.</p>\n<p>The addition of the third dose also appeared safe in the trial, the companies said.</p>\n<p>Given the immune response boost from a third dose, the companies said, a booster shot within six months to a year after the second shot might help maintain protection against&nbsp;symptomatic Covid-19.</p>\n<p>Pfizer and BioNTech are also conducting a larger late-stage study evaluating whether a third dose safely provides more protection. The companies said they expect those results shortly and will then submit the data to the FDA.</p>\n<p>The FDA is considering a broader booster strategy, which the agency could issue in the next few weeks.</p>\n<p>Two doses of the Pfizer-BioNTech shot, given three weeks apart, are authorized for people ages 12 years and older.</p>\n<p>Some physicians and scientists in the U.S. say there isn’t a clear answer yet on whether boosters are needed for the general population, partly because of evidence that shows vaccines continue to be highly effective at preventing severe disease.</p>\n<p>Studies indicate the vaccine is still highly effective in people&nbsp;six months after their second dose. Yet there is some evidence its efficacy might diminish over longer periods, and the shot isn’t as effective againstt&nbsp;he Delta variant, prompting research into adding a third dose.</p>\n<p>Last week, the FDA authorized a third dose of an mRNA vaccine like the Pfizer-BioNTech shot&nbsp;for certain people with weakened immune systems, in a bid to bolster their immune defenses against Covid-19.</p>\n<p>In the early-stage study looking at a booster among generally healthy people, subjects got a third 30-microgram dose, Pfizer and BioNTech said. The subjects received the extra dose eight to nine months after receiving their second dose.</p>\n<p>Then researchers measured in subjects their levels of neutralizing antibodies, which play a crucial role in protection against the virus, the companies said.</p>\n<p>The levels rose against the initial strain of the virus, as well as the Beta and Delta variants, the companies said. After the booster dose, neutralizing antibodies against the variants were similar to the earlier strain, the companies said.</p>\n<p>Pfizer presented some of the scientific data during its second-quarter earnings presentation last month, but hasn’t detailed the results yet. After a third shot, antibody levels were up more than five times among people ages 18 to 55 and more than 11 times in people ages 65 to 85, compared with two doses, according to Pfizer’s data.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech Seek FDA Clearance for Covid-19 Booster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech Seek FDA Clearance for Covid-19 Booster\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-17 07:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/pfizer-biontech-seek-fda-clearance-for-covid-19-booster-11629136057?mod=hp_lead_pos6><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Early-stage study shows third dose of vaccine offers a higher level of protection, companies say\nThe addition of a third dose appeared safe, Pfizer and BioNTech said. A Covid-19 vaccination at a ...</p>\n\n<a href=\"https://www.wsj.com/articles/pfizer-biontech-seek-fda-clearance-for-covid-19-booster-11629136057?mod=hp_lead_pos6\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://www.wsj.com/articles/pfizer-biontech-seek-fda-clearance-for-covid-19-booster-11629136057?mod=hp_lead_pos6","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166738043","content_text":"Early-stage study shows third dose of vaccine offers a higher level of protection, companies say\nThe addition of a third dose appeared safe, Pfizer and BioNTech said. A Covid-19 vaccination at a Schwenksville, Pa., pharmacy.\nPfizer Inc. and partner BioNTech SE have submitted data to U.S. health regulators needed to cleara Covid-19 booster shot among the general public.\nThe companies said Monday they sent to the U.S. Food and Drug Administration results from a small, early-stage study showing a third dose of their vaccine generated higher levels of neutralizing antibodies against the original virus and against the Beta and Delta variants than the standard two-dose regimen.\nThe addition of the third dose also appeared safe in the trial, the companies said.\nGiven the immune response boost from a third dose, the companies said, a booster shot within six months to a year after the second shot might help maintain protection against symptomatic Covid-19.\nPfizer and BioNTech are also conducting a larger late-stage study evaluating whether a third dose safely provides more protection. The companies said they expect those results shortly and will then submit the data to the FDA.\nThe FDA is considering a broader booster strategy, which the agency could issue in the next few weeks.\nTwo doses of the Pfizer-BioNTech shot, given three weeks apart, are authorized for people ages 12 years and older.\nSome physicians and scientists in the U.S. say there isn’t a clear answer yet on whether boosters are needed for the general population, partly because of evidence that shows vaccines continue to be highly effective at preventing severe disease.\nStudies indicate the vaccine is still highly effective in people six months after their second dose. Yet there is some evidence its efficacy might diminish over longer periods, and the shot isn’t as effective againstt he Delta variant, prompting research into adding a third dose.\nLast week, the FDA authorized a third dose of an mRNA vaccine like the Pfizer-BioNTech shot for certain people with weakened immune systems, in a bid to bolster their immune defenses against Covid-19.\nIn the early-stage study looking at a booster among generally healthy people, subjects got a third 30-microgram dose, Pfizer and BioNTech said. The subjects received the extra dose eight to nine months after receiving their second dose.\nThen researchers measured in subjects their levels of neutralizing antibodies, which play a crucial role in protection against the virus, the companies said.\nThe levels rose against the initial strain of the virus, as well as the Beta and Delta variants, the companies said. After the booster dose, neutralizing antibodies against the variants were similar to the earlier strain, the companies said.\nPfizer presented some of the scientific data during its second-quarter earnings presentation last month, but hasn’t detailed the results yet. After a third shot, antibody levels were up more than five times among people ages 18 to 55 and more than 11 times in people ages 65 to 85, compared with two doses, according to Pfizer’s data.","news_type":1},"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894215151,"gmtCreate":1628828691073,"gmtModify":1631888076569,"author":{"id":"3580168616843436","authorId":"3580168616843436","name":"林欣霓","avatar":"https://static.tigerbbs.com/a28a5c6d65cfcd6a5024f3b15f4975e8","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580168616843436","idStr":"3580168616843436"},"themes":[],"htmlText":"Take 3rd dose for those&nbsp;weak immune system&nbsp;","listText":"Take 3rd dose for those&nbsp;weak immune system&nbsp;","text":"Take 3rd dose for those weak immune system","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894215151","repostId":"1127554137","repostType":4,"isVote":1,"tweetType":1,"viewCount":158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}